DBV Technologies (NASDAQ:DBVT) PT Raised to $5.00 at JMP Securities

DBV Technologies (NASDAQ:DBVT) had its price target upped by JMP Securities from $4.00 to $5.00 in a research note issued to investors on Wednesday morning, Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

Several other equities research analysts have also recently commented on DBVT. StockNews.com initiated coverage on DBV Technologies in a research note on Thursday, July 25th. They issued a hold rating for the company. HC Wainwright reduced their price target on DBV Technologies from $20.00 to $10.00 and set a buy rating on the stock in a research report on Wednesday, May 8th.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $0.94 on Wednesday. The stock has a fifty day moving average of $0.91 and a 200-day moving average of $1.32. The stock has a market capitalization of $90.70 million, a P/E ratio of -1.12 and a beta of 0.68. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $3.70.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 66.96%. During the same period last year, the business posted ($0.26) earnings per share. Equities research analysts forecast that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 50,986 shares of the company’s stock, valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.